Royalty Pharma plc (
RPRX) has surfaced in numerous news stories. It has been given an average recommendation of \"Moderate Buy\" by various brokerages. Prominent personalities such as
Jim Cramer lamented the company's recent lackluster performance, nonetheless, some foresee immense opportunities for its stock. Its share price was recently bumped to $39 at
BofA. In fact,
BNP Paribas Asset Management facilitated an increased position in RPRX. Despite murky financials, the stock continues to rally.
Overbrook Management Corp sold a notable number of shares, while hedge funds indicate high upside potential. The company will acquire royalty interests in
Geron's RYTELO for $125 million and declared a Q4 2024 dividend. Positive Q3 earnings were noted, alongside unusually high trading volume. Positive Q3 earnings results and a surge in revenues has been noted, fuelling optimism. New funding agreements have been established, including a $350 million royalty funding deal with
Syndax Pharmaceuticals. RPRX awarded an inaugural healthcare prize to
Michael Milken for his impact on cancer research, and shares purchased by multiple asset management firms. The company announces FDA approval milestones and closes a $905M deal.
Royalty Pharma Stocks News Analytics from Sun, 26 Nov 2023 08:00:00 GMT to Sat, 23 Nov 2024 10:08:44 GMT -
Rating 7
- Innovation -6
- Information 9
- Rumor -6
